Tag Archive for: SAB

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

/in

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

Read more

Destiny Pharma plc – Positive findings from recent SAB meeting

/in

Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board […]

Read more